Amarillo Biosciences, Inc. is engaged in developing biologics for the treatment of human and animal diseases. The Company is focusing its research on human health indications for the use of low-dose orally administered natural human interferon alpha, particularly for the treatment of Sjogren's syndrome, fibromyalgia, idiopathic pulmonary fibrosis and asthma. The Company owns or licenses 20 United States patents relating to low-dose oral natural interferon alpha. Since 1992, the Company has filed with the U.S. Food and Drug Administration, and there now are in effect, six Investigational New Drug Applications covering indicated uses for low-dose oral interferon alpha, including treatment of Sjogren's syndrome and fibromyalgia. The Company has completed two 24-week Phase III clinical trials of the use of interferon alpha lozenges in the treatment of primary Sjogren's syndrome.
